CIPH Ciphergen Biosystems (MM)

Presentations by Collaborators at the Johns Hopkins Medical Institutions FREMONT, Calif., April 4 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) highlighted today two studies being presented at the 97th annual American Association of Cancer Research (AACR) conference which is running from April 1-5 in Washington, D.C. In multiple previous studies, Ciphergen and its collaborators have discovered, identified, and validated seven serum/plasma biomarkers for the detection of ovarian cancer. In a study being presented today, researchers from The Johns Hopkins University School of Medicine, Righospitalet, University of Copenhagen, Denmark, and the Danish Cancer Society independently validated the seven biomarkers using prospectively collected serum samples. This study concluded that this seven biomarker panel in combination with CA- 125 improves the discrimination of ovarian cancer from benign pelvic masses, including endometriosis and benign ovarian cysts. The prospective nature of the study and the blinded training and testing provided an independent validation of the seven biomarkers. As part of Ciphergen's breast cancer program, researchers from The Johns Hopkins Medical Institutions, National Cancer Institute, and M.D. Anderson Cancer Center presented today at AACR the latest developments in a paper titled, "Discovery of serum proteomic biomarkers for the early detection of breast cancer- a multi-center study." The original study in this program by Li et al. (Clinical Chemistry 48(8) 1296-1304) published in 2002 detailed the discovery of three serum biomarkers that can improve detection of breast cancer. Two of the three markers have been identified and validated by two recent studies (Li et al. (Clinical Chemistry 51, p. 2229-2235) and Mathelin et al, (Breast Cancer Res Treatment 96, p. 83-90)). In this presentation at AACR, the researchers report the discovery of additional biomarkers in a multi-institutional study that improved the performance of the current biomarker panel. Identification and characterization of these biomarkers are currently underway. "These studies and others that will be featured at AACR demonstrate the potential for improved patient care as these discoveries are translated into new diagnostic and theranostic tests based on Ciphergen's SELDI ProteinChip(R) Technology," stated Gail S. Page, President and CEO of Ciphergen. About Ciphergen Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the predictive value and usefulness of the reported multi-marker panels in improving the detection of ovarian cancer from benign masses or in the early detection of breast cancer, and the ability of Ciphergen to identify and characterize additional biomarkers and to create diagnostic or theranostic tests that improve patient care. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the fact that the performance of these or any other multi-marker panels discovered by Ciphergen may not validate in subsequent studies or be developed into an assay that is useful to physicians and patients. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K dated March 17, 2006, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297 Web site: http://www.ciphergen.com/

Copyright